In vitro tumor growth inhibition by bispecific antibodies to human transferrin receptor and tumor-associated antigens is augmented by the iron chelator deferoxamine

Clinical Immunology and Immunopathology

Volumn 80, Issue 2, 1996, Pages 185-193

  Hsieh Ma, Sylvia T ^a   Shi, Tim ^a   Reeder, John ^a   Ring, David B ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; DEFEROXAMINE; MONOCLONAL ANTIBODY; TRANSFERRIN RECEPTOR; TUMOR ANTIGEN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COLORECTAL CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0030222273     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1996.0113     Document Type: Article

References (35)

1. 1. Cazzola, M., Bergamaschi, G., Dezza, L., and Arosio, P., Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: Achievements and prospects. Blood 75, 1903-1919, 1990.
2. 2. Lesley, J. F., and Schulte, R. J., Inhibition of cell growth by monoclonal antitransferrin receptor antibodies. MoL Cell Biol. 5, 1814-1821, 1985.
3. 3. Taetle, R., and Honeysett, J. M., Effects of monoclonal anti-transferrin receptor antibodies on in vitro growth of human solid tumor cells. Cancer Res. 47, 2040-2044, 1987.
4. 4. Trowbridge, I. S., Collawn, J., Jing, S., White, S., Esekogwu, V., and Stangel, M., Structure-function analysis of the human transferrin receptor: Effects of anti-receptor monoclonal antibodies on tumor growth. In "Biotechnology of Plasma Protein. Current Studies in Hematology and Blood Transfusion," (A. Albertini, C. L. Lenfant, P. M. Mannucci, and J. J. Sixma, Eds.), pp. 139-147, Krager, Basel, 1991.
5. 5. White, S., Taetle, R., Seligman, P. A., Rutherford, M., and Trowbridge, I. S., Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: Evidence for synergistic antiproliferative effects. Cancer Res. 50, 6295-6301, 1990.
6. 6. Taylor, C., Linden, H., Houghton, A., Kornfeld, S., Hect, T., and Taetle, R., Phase 1a trial of mouse IgA anti-transferrin receptor monoclonal antibody, 42/6 in patients with cancer. Proc. AACR 35, 218, 1994.
7. 7. Frankel, A. E., Ring, D. B., Tringale, F., and Hsieh-Ma, S. T., Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. J. Biol. Response Mod. 4, 273-286, 1985.
8. 8. Bjorn, M. J., Ring, D., and Frankel, A., Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res. 45, 1214-1221, 1985.
9. 9. Crews, J. R., Maier, L. A., Yu, Y. H., Hester, S., O'Briant, K., Leslie, D. S., DeSombre, K., George, S. L., Boyer, C. M., Argon, Y., and Bast, R. C., Jr., A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines. Int. J. Cancer 51, 772-779, 1992.
10. 10. Martell, L. A., Agrawal, A., Ross, D. A., and Muraszko, K. M., Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res. 53, 1348-1353, 1993.
11. 11. Ring, D. B., Hsieh-Ma, S. T., Shi, T., and Reeder, J., Antigen forks: Bispecific reagents that inhibit cell growth by binding selected pairs of tumor antigens. Cancer Immunol. Immunother. 39, 41-48, 1994.
12. 12. Boyer, C. M., Borowitz, M. J., McCarty, K., Jr., Kinney, R. B., Everitt, L., Dawson, D. V., Ring, D., and Bast, R., Jr., Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells. Int. J. Cancer 43, 55-60, 1989.
13. 13. Ring, D. B., Clark, R., and Saxena, A., Identity of BCA200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2. MoI. Immunol. 28, 915-917, 1991.
14. 14. Kemp, J. D., Smith, K. M., Kanner, L. J., Gomez, F., Thorson, J. A., and Naumann, P. W., Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor. Blood 76, 991-995, 1990.
15. 15. Pippard, M. J., Clinical use of iron chelators. In "Iron in Immunity, Cancer and Infammation" (M. de Souza and J. H. Brock, Eds.), pp. 1-361, Wiley, Chichester, UK, 1989.
16. 16. Kim, W. H., Chon, C. Y., Moon, Y. M., Kang, J. K., Park, I. S., and Choi, H. J., Effect of anticancer drugs and desferrioxamine in combination with radiation on hepatoma cell lines. Yonsei Med. J. 34, 45-56, 1993.
17. 17. Tomoyasu, S., Fukuchi, K., Yajima, K., Watanabe, K., Suzuki, H., Kawakami, K., Gomi, K., and Tsuruoka, N., Suppression of HL-60 cell proliferation by deferoxamine: Changes in c-myc expression. Anticancer Res. 13, 407-410, 1993.
18. 18. Helson, C., and Helson, L., Deferoxamine and human neuroblastoma and primitive neuroectodermal tumor cell lines. Anti-cancer Res. 12, 481-483, 1992.
19. 19. Richardson, D., Ponka, P., and Baker, E., The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res. 54, 685-689, 1994.
20. 20. Kann, H. W., Stahlhut, M. W., and Hann, C. L., Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology 11, 566-599, 1990.
21. 21. Kann, H. W., Stahlhut, M. W., Rubin, R., and Maddrey, W. C., Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 70, 2051-2056, 1992.
22. 22. Wang, F., Hailey, M., Ward, K., Elliot, R. L., and Head, J. F., Growth inhibition of rat 13762NF mammary adenocarcinoma by deferoxamine mesylate. Proc. AACR 35, 406, 1994.
23. 23. Donfrancesco, A., Deb, G., Dominici, C., Pileggi, D., Castello, M. A., and Helson, L., Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res. 50, 4929-4930, 1990.
24. 24. Voest, E. E., Neijt, J. P., Keunen, J. E., Dekker, A. W., van Asbeck, B. S., Nortier, J. W., Ros, F. E., and Marx, J. J., Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. Cancer Chemother. Pharmacol. 31, 357-362, 1993.
25. 25. Olivieri, N. F., Buncic, J. R., Chew, E., Gallant, T., Harrison, R. V., Keenan, N., Logan, W., Mitchell, D., Ricci, G., Skarf, B., Taylor, M., and Freedman, M. H., Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. TV. Engl. J. Med. 314, 869-873, 1986.
26. 26. Walker, J. A., Sherman, R. A., and Eisinger, R. P., Thrombocytopenia associated with intravenous desferrioxamine. Am. J. Kidney Dis. 6, 254-256, 1985.
27. 27. Weissman, A. M., Klausner, R. D., Rao, K., and Harford, J. B., Exposure of K562 cells to anti-receptor monoclonal antibody OKT9 results in rapid redistribution and enhanced degradation of the transferrin receptor. J. Cell BM. 102, 951-958, 1986.
28. 28. Herlyn, D., Herlyn, M., Ross, A. H., Ernst, C., Atkinson, B., and Koprowski, H., Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J. Immunolo. Methods 73, 157-167, 1984.
29. 29. Perez, M. S., and Walker, L. E., Isolation and characterization of a cDNA encoding the KS1/4 epithelial carcinoma marker. J. Immunol. 142, 3662-3667, 1989.
30. 30. Edwards, D. P., Grzyb, K. T., Dressler, L. G., Mansel, R. E., Zava, D. T., Sledge, G., Jr., and McGuire, W. L., Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res. 46, 1306-1317, 1986.
31. 31. Szala, S., Froehlich, M., Scollon, M., Kasai, Y., Steplewski, Z., Koprowski, H., and Linnenbach, A. J., Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc. Natl. Acad. Sci. USA 87, 3542-3546, 1990.
32. 32. Simon, B., Podolsky, D. K., Moldenhauer, G., Isselbacher, K. J., Gattoni-Celli, S., and Brand, S. J., Epithelial glycoprotein is a member of a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein. Proc. Natl. Acad. Sci. USA 87, 2755-2759, 1990.
33. 33. Litvinov, S. V., Velders, M., Bakker, H. A. M., Jan Fleuren, G., and Warnaar, S. O. Ep-CAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule. J. Cell Biol. 125, 437-446, 1994.
34. 34. Bridges, K. R., and Cudkowicz, A., Effect of iron chelators on the transferrin receptor in K562 cells. J. Biol. Chem. 259, 12970-12977, 1984.
35. 35. Kemp, J. D., Thorson, J. A., Stewart, B. C., and Naumann, P. W., Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: Evidence for a threshold model of iron deprivation toxicity. Cancer Res. 52, 4144-4148, 1992.